0 results for 'Eli Lilly'
Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.
Big Names Brandished in Effort to Restore $1.2B Cancer Treatment Verdict
The Federal Circuit ruled that a patent on a CAR-T treatment did not meet patent law's written description requirement. Jones Day and Irell & Manella are arguing for Bristol-Myers Squibb that the Federal Circuit has added judicial requirements to the statute that are virtually impossible for life sciences companies to meet.
With Billions at Stake, Supreme Court Dips Its Toes Into Biologic Drug Patents
The justices have asked for the solicitor general's views on a cert petition by Amgen in a case that could reinterpret patent law's Section 112 and the law of enablement.
Federal Judge Allows Teva's Migraine Med Patent Lawsuit to Proceed Against Eli Lilly
Teva argues that Eli Lilly induced infringement of two of Teva's patents that protect the methods for administering the drug for the treatment of "refractory" migraines, or for patients who failed on at least two prior migraine preventative treatments.
Law Journal Press | Digital Book
America Invents Act (AIA) Handbook: A Guide to the Patent Law Reform of 2011, The, 2015 Edition
Authors: Mary Anthony Merchant
View this Book
View more book results for the query "Eli Lilly"
A Quiet US Supreme Court Term Ahead for IP—With One Potential Explosion
The court is seeking the solicitor general's views on a case that could reset the court's much-maligned patent eligibility law. Beyond that, a fair use case over Andy Warhol artwork and patent dispute over biologic drugs offer a chance of fireworks.
Federal Circuit Tries to Wrap Its Arms Around Functional Biotech Patent Claims
The court signaled this week that Amgen may have claimed its cholesterol-fighting antibodies too broadly. But one judge suggested it might be time for the court to rethink its law of enablement.
Latham Lands Pharma Patent Litigator Adam Perlman From Williams & Connolly
The former co-chair of Williams & Connolly's patent litigation practice has counted Eli Lilly and Bayer among his clients. Latham leaders say his arrival will cement the firm's transition to the brand side of Hatch-Waxman litigation.
Congressional Fix for PTAB Appointments Problem Could Come at Cost
House IP subcommittee chairman Hank Johnson said threatening administrative patent judges' job security isn't the way to go. But ranking member Martha Roby suggests the PTAB has problems beyond appointments that need to be addressed.TRENDING STORIES
More from ALM
- Legal Speak at General Counsel Conference Midwest 2024: Mike Andolina, Partner, White & Case 1 minute read
- Legal Speak at General Counsel Conference Midwest 2024: Carolyn Burbrink, Uber Director of Volume Mobility Safety and Insurance Litigation 1 minute read
- Legal Speak at General Counsel Conference Midwest 2024: Vaishali Rao, Hinshaw & Culbertson Partner 1 minute read
Resources
Corporate Transparency Act Resource Kit
Brought to you by Wolters Kluwer
Download Now
Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now